COVID-19 IND Moves to Phase 2



An Ivestigational New Drug Application (IND) for the use of FSD201 (ultramicronized palm itoylethanolamide, or ultramicronized PEA) to treat COVID-19, the disease caused by the SARS-CoV-2 virus (the "FSD201 COVID-19 Trial") was announced by FSD Pharma Inc. The FSD201 COVID-19 Trial will be a randomized, controlled, double-blind, multicenter study, conducted at 25-30 sites in North America to assess the efficacy and safety of FSD201 dosed at 600mg or 1200mg twice-daily, together with standard of care ("SOC") compared to SOC alone in hospitalized patients with documented COVID-19 disease.

Philadelphia, USA | Blainville, Canada | Cambridge, UK | Semengoh, Malaysia | Hangzhou, China